Innovations in cancers of the central nervous system
- Submission status
- Closed
- Submission deadline
This Collection aims to highlights the latest advances in research in brain cancers, with a focus on adult diffuse gliomas, glioblastomas, meningiomas and metastatic brain tumors. Tumors affecting the brain cause substantial morbidity and mortality and there is a significant need for improved detection, non-invasive monitoring strategies and more effective and durable treatments. The focus of the collection will be on recent advances in basic, translational and clinical research as well as offer expert commentary on strategies to move brain cancer diagnostics and therapeutics forward.
Topics of interest include:
- Advances in liquid biopsy for diagnosis and monitoring of nervous system cancers
- Preclinical disease models (patient-derived xenografts, organoids, genetically engineered models)
- Innovations in Immunotherapy
- Metabolic dysregulation in glioma
- Targeted therapies and resistance in brain tumors
- Cancer neuroscience and tumor-microenvironment
- Advances in imaging techniques
- Strategies for increasing CNS permeability of therapeutic agents
- Applications of Artificial Intelligence/Machine Learning to brain cancers
This Collection supports and amplifies research related to SDG 3.
Editors
-
Julie J. Miller
Massachusetts General Hospital, Harvard Medical School, USA.
-
Albert Kim
Massachusetts General Hospital, Harvard Medical School, USA.
All articles have undergone npj Precision Oncology's standard peer review process and have been subject to all the journal’s standard policies. This includes the journal’s policy on competing interests. The Editors declare no competing interests with the submissions which they have handled through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.
If accepted for publication, an article processing charge applies (with standard waiver policy). If your institution or country has an open access agreement with Springer Nature, you may publish your article OA at no cost or in some cases with the costs partially funded (see details here).
All Collections are open for submissions from all authors – and not by invitation only – on the condition that the manuscripts fall within the scope of the Collection and of npj Precision Oncology more generally.
Manuscripts submitted to an open Collection may be considered unsuitable for inclusion, particularly if they fall outside the scope of the Collection. In such cases, the authors will be notified by the editorial office and their manuscript can be considered as a regular npj Precision Oncology submission.
npj Precision Oncology’s in-house editors reserve the right to assume responsibility for the management of a Collection at any stage.
